Pakistan

BMI View: Despite the significant presence of multinationals in Pakistan and the country's market potential, the leading international firms' local activity remains minimal, largely... 2011-08-19

BMI View: While Pakistan boasts a substantial population of 174mn people, annual per-capita expenditure on pharmaceuticals is very modest at just US$10. Despite expected economic progress,... 2011-06-30

BMI view: There are significant hurdles on GlaxoSmithKline Pakistan's road towards fully exploiting Pakistan's untapped potential, not least the country's weak distribution infrastructure,... 2011-05-18

Developed state underperformance remains a recurring theme within our Industry analysis. We remain concerned about US labour market weakness and its impact, particularly on consumer... 2010-09-28

GlaxoSmithKline Pakistan's financial performance has been impaired by a challenging business environment, according to the company's senior executive. In an interview with Bloomberg,... 2010-07-09

BMI believes the strategy adopted by Searle Pakistan is advisable given the challenging operating environment in the South Asian country. The Karachi-based drugmaker dramatically... 2010-04-21

Combined sales of prescription drugs and over-the-counter (OTC) medicines in Pakistan are forecast to increase from PKR132bn (US$1.62bn) in 2009 to PKR144bn (US$1.64bn) in 2010. Due... 2010-04-20

Pakistan's US$1.62bn pharmaceutical market is the 10th largest in Asia Pacific, behind the Philippines (US$2.58bn) and ahead of Vietnam (US$1.53bn). Annual per-capita spending on medicines... 2010-04-19

Healthcare spending in Pakistan is expected to increase from PKR227bn (US$2.76bn) in 2009 to PKR257bn (US$2.86bn) in 2010. Due to depreciation of the rupee, this equates to growth... 2010-01-18

The pharmaceutical pricing regime in Pakistan is typical of an emerging market and far below international standards. Both generic drugs and patented products are subject to price... 2010-01-05